Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Medicinal cannabinoids might not be effective for treating mental disorders

Staff Writer
Staff Writer 3 years ago
Updated 2019/10/31 at 12:36 AM
Share
SHARE

After a comprehensive systematic review of 83 studies, a team of researchers at the National Drug and Alcohol Research Centre (NDARC) could not find considerable evidence that medicinal cannabinoids reduce the severity of mental disorders. The results were published in The Lancet Psychiatry.

The findings were reached by examining particular databases between 1980 and 2018, which included MEDLINE, PsycINFO, Embase, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Clinical Trials. In total, researchers went through the data of an estimated 3,000 people.

From those databases, the aim was to establish, among adult participants, if medicinal cannabinoids provide any potential therapeutic effect for symptoms of the following six mental disorders: depression, anxiety, post-traumatic stress disorder (PTSD), psychosis, Tourette syndrome, and attention-deficit hyperactivity disorder (ADHD).

“We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders,” writes Emily Stockings, co-author of the study.

“83 eligible studies (40 randomised controlled trials) were included: 42 for depression (23 randomised controlled trials), 31 for anxiety (17 randomised controlled trials), eight for Tourette syndrome (two randomised controlled trials), three for ADHD (one randomised controlled trial), 12 for post-traumatic stress disorder (one randomised controlled trial), and 11 for psychosis (six randomised controlled trials),” Stockings explained.

“The safety of medicinal cannabinoids for these mental disorders was also examined.”

According to the findings, the benefits of medicinal cannabis for the mental disorders examined in the study were drastically low, concluding with insufficient evidence for effective treatment.

“There is scarce evidence to suggest that cannabinoids improve depressive disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder, or psychosis,” Stockings stated. “There remains insufficient evidence to provide guidance on the use of cannabinoids for treating mental disorders within a regulatory framework.”

“Further high-quality studies directly examining the effect of cannabinoids on treating mental disorders are needed.”

The study was funded by the National Institutes of Health, Commonwealth Department of Health, Australia, the Australian National Health and Medical Research Council, and Therapeutic Goods Administration.

You Might Also Like

Researchers find high cholesterol may not raise the risk of dementia

Study unveils the leisure activities that may lower the risk of dementia

MIT study shows how microglia can contribute to Alzheimer’s disease

New paper refutes theory that the human brain shrank 3,000 years ago

New study finds that people with autism are more skilled at reading emotions in cartoons

TAGGED: cannabinoids, tetrahydrocannabinol
Staff Writer October 31, 2019
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article More than 67 million residents in the U.S. now speak a language other than English at home
Next Article New research links aerobic exercise to improved memory in older adults

Recommended

Clinical

Researchers find high cholesterol may not raise the risk of dementia

1 Min Read
Clinical

Study unveils the leisure activities that may lower the risk of dementia

1 Min Read
Clinical

MIT study shows how microglia can contribute to Alzheimer’s disease

1 Min Read
Clinical

New paper refutes theory that the human brain shrank 3,000 years ago

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?